PharmaCyte Closing i
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
May 21, 2018 09:20 ET | PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
March 08, 2017 16:05 ET | OncoMed Pharmaceuticals, Inc.
Demcizumab and Tarextumab Randomized Phase 2 Data Expected 1H 2017 Anti-TIGIT IND Accepted; GITRL-Fc IND Expected 1H 2017 OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30...
PharmaCyte Going Hea
PharmaCyte Going Head to Head with Eli Lilly's Pancreatic Cancer Drug in New Clinical Trial
January 24, 2017 09:10 ET | PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - January 24, 2017) - Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments....
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Announces Year-End Cash Balance and 2017 Outlook
January 05, 2017 08:30 ET | OncoMed Pharmaceuticals, Inc.
Enters 2017 with $184.6 Million in Cash Potential for Five Program Opt-ins Totaling Over $170M Anti-TIGIT (I/O#2) IND Filed REDWOOD CITY, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- OncoMed...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Pharmaceuticals Appoints Perry Karsen to Board of Directors
January 06, 2016 08:30 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc., (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Achieves $72.5 Million in Milestone Payments From Celgene; Announces Year-End Cash Balance
January 05, 2016 08:30 ET | OncoMed Pharmaceuticals, Inc.
$70 Million Safety and $2.5 Million Clinical Candidate Designation Milestones Achieved Enters 2016 with $227 Million in Pro-Forma Cash REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) --...
CLSA Logo
Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony
November 09, 2015 10:10 ET | California Life Sciences Association
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- California Life Sciences Association (CLSA), the leading voice to drive innovation for California's life sciences sector, today announced...
Mesoblast Chairman's Address to 2015 Annual General Meeting
October 22, 2015 02:00 ET | Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting. This has been another exciting and productive year in the history of our...
PharmaCyte Biotech A
PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
October 15, 2015 09:25 ET | PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - October 15, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) advanced pancreatic cancer treatment of Cell-in-a-Box® capsules + low-doses of ifosfamide has outperformed Eli...
Celgene May Also Wan
Celgene May Also Want to Take Notice of PharmaCyte Biotech
July 24, 2015 09:00 ET | PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 24, 2015) - A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a...